![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.indianpharmapost.com/news/biocon-posts-q1-fy25-pat-higher-at-rs-660-cr-16003
https://www.reuters.com/business/healthcare-pharmaceuticals/indias-biocon-posts-q1-profit-rise-sale-branded-formulations-business-2024-08-08/
https://www.cnbctv18.com/market/biocon-share-price-usfda-observations-biologics-unit-cnbctv18-accesses-form-483-details-here-19456740.htm
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215759
https://www.indianpharmapost.com/news/usfda-completes-inspection-at-biocon-biologics-facilities-in-bengaluru-15937
https://economictimes.indiatimes.com/industry/healthcare/biotech/biocon-gets-4-observations-from-usfda-for-andhra-pradesh-facility/articleshow/111192847.cms
https://www.moneycontrol.com/news/business/companies/biocon-seeks-partner-to-test-generic-wegovy-ozempic-in-china-12752897.html
https://www.biocon.com/biocon-limited-signs-exclusive-licensing-and-supply-deal-for-the-commercialization-of-liraglutide-in-south-korea-with-handok-inc/
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-biocon-units-biosimilar-blockbuster-eye-drug-eylea-2024-05-20/